VivoSeq
Oncology

Alveolar Soft Part Sarcoma

19

Pipeline Programs↗

6

Active Trials↗

12

Companies Involved↗

Alveolar Soft Part Sarcoma is an emerging landscape with 19 programs across 12 companies. The most active players are Aduro Biotech, Inc., Genor Biopharma Co., Ltd., Merck & Co.. 5 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

11/100

Mech. Concentration

8/100

Completion Rate

83/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Aduro Biotech, Inc.

1 program

Phase 1G

Genor Biopharma Co., Ltd.

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 2Roche logo

Roche

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2P

Prism Pharmaceuticals

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

79%

Small molecule

15 of 19 classified programs — the dominant modality here.

21%ALL OTHERSMonoclonal antibody316%Cell therapy15%

Small molecule leads; the ring shows all 19 classified programs, each share of the total. Modality classified for 100% of 20 pipeline programs.

Analysis

Trial Status

14

clinical trials

Completed5 · 36%
Recruiting3 · 21%
Active, not recruiting2 · 14%
Unknown status2 · 14%
Terminated1 · 7%
Not yet recruiting1 · 7%

Clinical Trials

Trial Activity

14 trials

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
Recruiting·AAdvenchen Laboratories, LLC·Phase 3·NCT03016819·325 enrolled
A Feasibility Phase I Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Recruiting·National Cancer Institute (NCI)·Phase 1·NCT06066138·30 enrolled
A Phase 2 Study of Atezolizumab With Selinexor in Alveolar Soft Part Sarcoma (AXIOM)
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT05333458·27 enrolled
CAR T Therapy With GCAR1 for Relapsed Alveolar Soft Part Sarcoma
Active, not recruiting·UUniversity of Calgary·Phase 1·NCT06813417·1 enrolled
GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma (CLIC-YYC-GPNMB-02)
Active, not recruiting·AAHS Cancer Control Alberta·Phase 1·NCT06789081·1 enrolled
A Study to Determine the Safety and Effectiveness of the Investigational Cellular Therapy GCAR1 in a Patient With Alveolar Soft Part Sarcoma
Not yet recruiting·UUniversity of Calgary·Phase 1·NCT07104682·1 enrolled
Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma
Completed·National Cancer Institute (NCI)·Phase 2·NCT00942877·53 enrolled
GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma
Completed·AAHS Cancer Control Alberta·Phase 1·NCT06827886·1 enrolled
Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
Completed·National Cancer Institute (NCI)·Phase 2·NCT01391962·34 enrolled
Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas
Completed·—·Phase 2·NCT02636725·33 enrolled
Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma
Completed·—·Phase 1·NCT00258687·12 enrolled
Pazopanib for Metastatic Alveolar Soft Part Sarcoma
Terminated·SSeoul National University Hospital·Phase 2·NCT02113826·6 enrolled
A Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS)
Unknown status·IInstitute of Cancer Research, United Kingdom·Phase 2·NCT01337401·36 enrolled
Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226)
Unknown status·GGenor Biopharma Co., Ltd.·Phase 2·NCT03623581·35 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)